WO2000051491A1 - Methode visant a administrer un medicament par inhalation de maniere sure et efficace - Google Patents

Methode visant a administrer un medicament par inhalation de maniere sure et efficace Download PDF

Info

Publication number
WO2000051491A1
WO2000051491A1 PCT/US2000/005559 US0005559W WO0051491A1 WO 2000051491 A1 WO2000051491 A1 WO 2000051491A1 US 0005559 W US0005559 W US 0005559W WO 0051491 A1 WO0051491 A1 WO 0051491A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
drug
inhalation
dosing
drag
Prior art date
Application number
PCT/US2000/005559
Other languages
English (en)
Inventor
Michael E. Placke
Anthony R. Imondi
Mirjam C. Gerber
Ronald R. Moutvic
Original Assignee
Battelle Memorial Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Battelle Memorial Institute filed Critical Battelle Memorial Institute
Priority to AU33936/00A priority Critical patent/AU3393600A/en
Publication of WO2000051491A1 publication Critical patent/WO2000051491A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/02—Inhalators with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles

Definitions

  • the invention concerns the administration of drugs to the pulmonary system (particularly the lung) in the proper dosage, at the appropriate site so that a patient is treated in a safe and effective manner.
  • bronchodilators via inhalation
  • aerosol technology As these agents have a wide therapeutic ratio, many of the potential concerns with this route of delivery have not been addressed.
  • issues such as precise and reproducible dosing and environmental exposure risks must be addressed.
  • the concept of delivering drugs for the treatment of respiratory diseases directly to the target organ is certainly attractive. Much higher local drug exposure can be achieved with doses considerably lower than those that would be required for systemic administration, resulting in lower exposure of non-respiratory tract tissues to potentially toxic drug levels.
  • the administration of pentamidine via aerosol has received regulatory approval for the prevention of Pneumocystis carinii infection in high risk patients.
  • Aerosol delivery is also approved for tobramycin and is being investigated for ticarcillin antifungal agents such as amphotericin, and antiviral agents including ribavirin.
  • ticarcillin antifungal agents such as amphotericin, and antiviral agents including ribavirin.
  • the administration of cyclosporine by inhalation is being studied for the treatment of allograft rejection in patients who have undergone lung transplant.
  • Various therapeutic agents for use in patients with cystic fibrosis have been evaluated, and some, for example Pulmozyme, are commercially available.
  • Pulmozyme are commercially available.
  • the concept of treating pulmonary malignancies, either primary or metastatic, by delivering chemotherapeutic agents or biologic response modifiers directly to the lungs has received little attention
  • Footnotes a Swiss mice, mtrape ⁇ toneal route b P388 and L1210 leukemia, B 16 melanoma, Lewis lung carcinoma. "K1210 leukemia Mice e M109 lung carcinoma Rats, oral route s Guinea pigs
  • Table 1 illustrates very clearly the dilemma faced when treating patients with antineoplastic drugs.
  • the dose has to be controlled very carefully. This table shows 50 are not far apart.
  • doxorubicm an effective dose of 8 mg/kg(body weight) is not far away from the LD 50 dose of 14.4 mg/kg. Doubling the effective dose effectively puts the dose near the LD 50 level where about half the animals would be expected to die.
  • Paclitaxel exhibits similar properties as doxorubicin.
  • the drug 5-FU is somewhat less toxic than doxorubicin or paclitaxel but exhibits similar properties.
  • non-antineoplastic drugs such as those used to treat airway disease or for anti- inflammatory drugs the differences between LD 50 and effective dose are in excess of 1000.
  • these latter drugs e.g. albuterol, triamcinolone
  • a doubling or tripling of the effective dose is inconsequential relative to toxic dose or lethal dose.
  • the method contemplates the development of a patient specific plan for administering a drug by inhalation.
  • the plan is typically based on the patients disease, disease state, age, the aerosol generator used, the drug to be administered, particle or aerosol size and other drug, carrier, excipient or formulation characteristics, the number of dosing and preparatory breaths, type of breath (e.g. deep or shallow), the pulmonary system distribution and the inhaled amount of a tracer material; apparatus parameters; patient breathing or pulmonary characteristics and the like.
  • the tracer material typically has deposition characteristics substantially the same as the drug to be administered or its administration is corrected for the difference.
  • Inhalation device settings, number of dosing breaths, type of breaths, and so on are typically calculated from information obtained in tests developed in the patient specific plan.
  • the patient specific plan provides a safe and effective method for delivering a predetermined dose of drug to the total body, to the pulmonary system, or to a specific site in the patient's pulmonary system.
  • the invention concerns a method of treating a patient having a disease with a drug by inhalation in a safe and effective manner where the method includes the steps of (a) performing a first filter test on the patient with a tracer material and an inhalation device, wherein the patient is not exposed to the tracer material; to obtain a first set of data; (b) performing a second filter test on the patient with a tracer material n an n a a on ev ce, w ere n e pa en n a es e racer ma er a ; o o a n a second set of data; (c) optionally performing a deposition pattern test on the patient to obtain a third set of data; (d) determining from the first, and second set of data, and optionally from
  • the method contemplates safely and effectively treating a patient exhibiting a neoplastic disease with an antineoplastic drug by inhalation by the steps of
  • NDP Selected Drug Dose (mg) ⁇ Drug output from aerosol generator per dosing breath (mg/breath) ⁇ Deposition efficiency (%/100)
  • Fig 1 is a schematic drawing of a typical inhalation device and system for administration of drug according to the invention.
  • Fig 2 is a schematic drawing of the details of the invention for the patient interface and filters used with the filter tests.
  • the method contemplates the development of data from a test or tests conducted on the patient prior to administering the drug by inhalation.
  • the data include but are not limited to particle or aerosol size and other characteristics, the minimum number of dosing breaths for good distribution, type of breath (e.g. deep, intermediate, or shallow), the pulmonary system distribution and the inhaled amount of a tracer material; apparatus parameters; patient breathing or pulmonary characteristics; and the like.
  • the tracer material typically has deposition characteristics substantially the same as the drug to be administered or the administration of drug is corrected for this difference. In practice having the tracer material have the same aerosol characteristics as the drug is preferred and practical in a real clinical device.
  • the invention concerns a method of treating a patient having a disease with a drug by inhalation in a safe and effective manner where the method includes the steps of (a) administering a tracer material to the patient by inhalation with an inhalation device; (b) determining the amount deposited and optionally the deposition pattern of the tracer material in the patient; (c) determining from the amount of deposited tracer material, and optionally from the deposition pattern of the tracer material; the dosing parameters required to administer a predetermined dose of drug; and (d) administering the drug to the patient with the inhalation device using the determined dosing parameters.
  • the inhalation device typically used with the present invention may be any inhalation device that is capable of delivering the desired amount of drug or antineoplastic drug dose having the required aerosol properties for proper deposition such as particle size, weight, charge, and so on.
  • Typical devices include those generally used in the application of aerosols to patients for treatment of disease conditions.
  • One preferred device is a pulmonary dosing system disclosed in US regu ar pa en app ca on en e u monary os ng ys em an e o e contemporaneously herewith on March 5, 1999, Serial No. 09/263,986, having the same assignee as the present application, the disclosure of which is incorporated by reference as if fully rewritten herein.
  • the inhalation device disclosed in the aforementioned application will be referred to hereinafter as the Battelle inhalation device.
  • Drug - as used throughout the specification the term "drug” should be interpreted to include any appropriate respirable, therapeutically active material useful in the treatment of disease. While the method can be used with any drug, the method finds particular usefulness with drugs that are toxic or highly toxic and/or that present narrow therapeutic windows.
  • Antineoplastic drug as used throughout the specification the term "antineoplastic drug” should be interpreted to include any appropriate respirable, therapeutically active antineoplastic material.
  • Antineoplastic material as used throughout the specification the words should be interpreted to include materials useful in the treatment of cell growth where the growth is uncontrolled and progressive. Typical terms that are included in this category to describe uncontrolled cell growth are cancer, tumor, neoplasm, neoplasia and the like.
  • Dosing Breath The inhalation breath which carries the tracer material aerosol or drug aerosol to the appropriate site in the pulmonary system (e.g. a deep inspiration dosing breath will favor deposition deep in the respiratory tract).
  • TDD Total Deposited Dose
  • DE Deposition Efficiency
  • Pulse volume The volume of drug solution (rtiL) aerosolized per activation of the aerosol generator.
  • the useful pulse volume for different types of aerosol generators is typically in the range of about O.OOlmL to about 0J mL.
  • the pulse volume should be substantially the same in aerosol generators that are used for the filter tests and in drug administration.
  • the aerosol generator was a nebulizer having a mean pulse volume of about 0.023 mL that ranged from a g o . m o a ow o . m . narrow range s es as exp a ne below.
  • Drug/pulse The amount of drug (in mg) aerosolized per activation (pulse) of the nebulizer.
  • D/P concentration of the drug solution (mg/mL) x pulse volume (mL). This pulse is pulse available for inhalation.
  • the drug is doxorubicin but may be any antineoplastic drug capable of being inhaled.
  • Total Doxorubicin Dose The total amount of doxorubicin which should be administered (total deposited dose x body surface area (BSA)).
  • Dosing parameters refers to the parameters used to control exposure of the patient to a drag or a tracer material.
  • the dosing parameters that are determined are the number of breaths that the patient should take to receive the predetermined dose of drag.
  • other dosing parameters that can be determined by the method of the invention include (1) time, such as the measurement of exposure time during the breathing cycle as one of the set of data measured in the filter tests during which the patient is exposed to a tracer material and determining the corresponding time that the patient should be exposed to a drag during the breathing cycle in which drug is administered to the patient; (2) weight or volume reduction in the supply of tracer material or drag at the aerosol generator, the measurement of weight or volume reduction at the aerosol generator during the filter tests would then be used to determine the weight or volume reduction in the supply of drug; (3) the converse of (2) would be track the amount of tracer material used and to monitor the patients use of drug in the supply of drug at the aerosol generator; (4) and in a final embodiment the amount of aerosol that is generated by the aerosol generator during the filter tests and drug administration session.
  • time such as the measurement of exposure time during the breathing cycle as one of the set of data measured in the filter tests during which the patient is exposed to a tracer material and determining the corresponding time that the patient should be exposed to
  • NDB Number of Dosing Breaths
  • NDB Total Doxorubicin Dose (mg) ⁇ Drug Amount/Pulse (mg) DE racer ma e a - a ma er a a s e ec a e, e racer ma e a may con a n radioactive isotopes with short half-lives that upon disintegration produce emissions that are detectable by imaging or other radioactive measurement techniques (e.g. Tc- 99m DTPA and the like). Although only Tc-99m DTPA has been used in the present examples it is contemplated that Tc-99m attached to other molecules is useful in the invention as are other types of isotopes.
  • the tracer material is typically in the form of a powdered particulate or an aerosol.
  • the tracer is typically used alone or physically mixed with or chemically attached to another material with which it forms a predetermined particle or aerosol size or range of sizes.
  • the tracer material may be fluorescent, absorbent, colored, dense, or in any form where a detectable signal may be obtained.
  • Tc-99m and the like the total amount of Tc-99m may range from 0J mCi to 10 mCi but preferably about 1 mCi to 3 mCi.
  • the actual amount of Tc-99m placed into the nebulizer may be determined by any suitable means for detecting gamma radiation, e.g. gamma camera or gamma well counter.
  • Substantially impaired pulmonary system means that there are areas of the lung that have substantially complete blockage of at least some portions of the pulmonary system such that the drug would concentrate in certain regions at concentrations likely to produce toxicity. Also cases where the patient is unable to have the drag delivered to areas of the pulmonary system (e.g. portions of the deep lung) so that the drag concentrations in the proximal airway or larynx would cause laryngitis, etc.
  • Substantially normal pulmonary system means that based on examination of the patient, including any pulmonary test, the patient is functioning substantially as a normal patient. Further, the pulmonary system appears to be in a condition where the drug can be distributed uniformly or distributed to the target region of the pulmonary system.
  • Low risk category with regard to the administration of the drag means that from examination of the patient including any pulmonary test the patient is functioning substantially as a healthy normal person. There is a relative high probability that the patient would not experience toxicity from the inhaled drug dose.
  • High risk category with regard to the administration of the drug means that the patient is likely to experience toxicity or other adverse reactions if the drug is inhaled.
  • ne o e ma or pro ems w n a a ona c emo erapy s e e very o accurate amounts of drug to a patient. It is believed that this factor is largely responsible for the fact that inhalational chemotherapy, pioneered by Shevchenko in Russia in 1968, and Sugawa and Tatsumura in Japan in 1970 and 1983 respectively, has not been universally accepted for cancer treatment in the pulmonary tract.
  • Tc-99m scintigraphy is a well-known medical diagnostic and research procedure in pulmonary medicine. This procedure has been used to show how an inhaled aerosol distributes in the respiratory tract and has aided in the evaluation of new improved inhalation drug devices. It has now been found that the use of tracer materials such as Tc-99m in scintigraphy provides a safe and useful tool in controlling and delivering the correct amount and pulmonary distribution of highly toxic drags such as antineoplastic drugs to be given to patients by inhalation.
  • patients who are candidates for inhalational chemotherapy using highly toxic drugs or drugs with narrow therapeutic windows will undergo a first and second filter test with a quantity of tracer material that mimics the deposition pattern of the drag to be administered.
  • the tracer material will contain particles having Tc-99m as a tracer.
  • the first filter test will have an inhalation filter that filters out all tracer material that the patient would have inhaled.
  • a second filter test is performed but the inhalation filter is removed and the patient actually inhales the tracer material. Data from the first and second filter tests will be used to determine the amount of tracer material that is retained in the body of the patient.
  • the distribution of the inhaled Tc-99m in the pulmonary system can be determined by the usual methods (such as with a gamma camera).
  • the information can en e use o e erm ne e n a a on con ons or a m n s er ng e rag o the patient.
  • inhalation conditions typically include one or more of the following, but is not limited by the list, the various settings of an inhalational device, breathing pattern of a patient, aerosol particles sizes, number of dosing breaths to be taken by the patient, the time length of a dosing period for administering a desired dose to the patient, volume or weight of drag and carrier to be aerosolized, and so on.
  • Aerosols are generated by suspending particles of a solid or a liquid in a gaseous medium.
  • devices for the generation of aerosols for inhalation that are in clinical use. These include metered dose inhalers, dry powder inhalers and nebulizers. The device used depends on the medical indication, the formulation, and the characteristics of the agent administered. Any of these devices are useful in the present invention as long as aerosols having desired properties are obtained.
  • Metered dose inhalers utilize a liquid propellant provided in a container and equipped with a metering valve that dispenses a constant volume of a solution or suspension of the drug in the propellant.
  • Dry powder inhalers do not use a propellant. They are breath-activated and therefore, patient coordination is not as important an issue. Many of these devices are designed to utilize the patient's inspiratory effort for aerosol dispersion and delivery of the drug powder to the lung.
  • the drug is formulated in a filler and contained in a capsule, which is placed in the device and punctured to release the powder. Both single load and multidose systems are available.
  • Aerosol formation by nebulizers is typically achieved by a high- velocity airstream forcing a solution or suspension of the drug through a liquid critical orifice (jet nebulizers), ultrasonically by the vibration of a piezoelectric crystal (ultrasonic nebulizers), by other methods such as electrical forces, or by combinations of the above.
  • jet nebulizers ultrasonically by the vibration of a piezoelectric crystal
  • ultrasonic nebulizers ultrasonically by the vibration of a piezoelectric crystal
  • electrical forces or by combinations of the above.
  • nebulizers are typically activated by pa en resp ra on an rag epos on s epen en upon ow ra e. ere ore, patient cooperation and coordination is not as critical as with metered dose inhalers.
  • Electrohydrodynamic aerosol generation devices are particularly useful for the practice of the present invention because they can generate aerosols having the needed properties and a very small variation the particle sizes.
  • Electrohydrodynamic aerosol generation is a process where bulk solutions are aerosolized using electrical forces.
  • the fluid to be aerosolized flows over a region of high electric field strength. When it does so, it receives a net electric charge that tends to stay on the surface of the fluid.
  • the repelling force of the surface charge balances against the surface tension of the material, and a cone is formed (known as a Taylor cone).
  • the tip of the cone has the greatest concentration of charge, and at this point, the electrical force overcomes the surface tension, generating a thin jet of fluid.
  • the jet breaks up into droplets of more or less uniform size, which collectively form a cloud.
  • the charge provides a mechanism for improved adhesion.
  • the droplets are typically discharged, by exposing the cloud to a stream of ions having an opposite polarity. The result is an aerosolized solution having a monodispersed droplet size and near zero velocity. Such a cloud is particularly desired in medical pulmonary applications such as with the present invention.
  • the method may use any aerosol generator that can reliably generate an aerosol having the required properties.
  • the method for safely and effectively treating a patient exhibiting a disease with a drug by inhalation first contemplates developing data useful for determining the proper inhalation conditions for administration of the drug to the patient.
  • the data is developed by testing a patient with an inhalation device that is the same device or substantially the same device as that which will actually be used to administer the drag.
  • the typical inhalation device 100 includes an aerosol generator 110 that provides a supply of aerosol via connection to 111 to patient interface 120.
  • An air or gas supply 130 is typically connected to the aerosol generator 110, via connec on , an or o e ne v a connec on ne , an or o e pa en interface 120.
  • connection lines 131, 132, or 133 may be needed.
  • device 100 includes an exhaust filter 140 connected to patient interface 120 via connection line 141 for filtering exhaled and blow-by gases to remove drag or tracer materials.
  • a check valve 144 or similar device for maintaining one directional flow may be used as needed in the device such as connected to the outlet of exhaust filter 140 via connection line 143 or in other locations. If the valve is located at the outlet of exhaust filter 140 it will not be contaminated unless there is a leak in the exhaust filter 140.
  • Control unit 150 for controlling various aspects of the inhalation device 100 may include signal processing means, memory, software for control of various functions of the device, sensors, operator interface means such as printers, video screens, lights, sound devices and the like that provide visual, acoustic, or printed indications to an operator.
  • a typical control unit 150 may include a PC or similar computer unit and associated software.
  • the software may be typical of that used in the art for controlling gas flow, liquid flow, on-off cycles, temperature; for calculating breath cycles, duration of breaths, and the like.
  • electrical or other sensing and control lines 153 are used to interconnect the various portions of the device 100 as shown in Figure 1.
  • look up tables representing calculations for body surface area, lung surface area or volume, scintigraphic readings, risk factors, and other measurements needed for calculations are included.
  • a further typical embodiment includes a neural network in control unit 150.
  • An optional plenum 109 may be used at the outlet of aerosol generator 110 in some versions of the inhalation device as in the Battelle inhalation device.
  • Plenum 109 functions to receive aerosol from the aerosol generator 110 and to allow the aerosol to slow down and stabilize prior to inhalation by the patient via connection line 111 and patient interface 120.
  • Plenum 109 may optionally have its own supply of air from air supply 130 via line 134.
  • plenum 109 When plenum 109 is not present aerosol generator 110 is connected directly to the patient interface 120 via line 111.
  • r supp y ows an pressures to t e va ous pa s o e n a a on ev ce
  • control unit 150 Air pressure and flow requirements will vary depending on the application, aerosol generator and so on.
  • the aerosol generator 110 is a nebulizer that requires high-pressure airflow to produce the aerosol.
  • Container 190 encloses a tracer material formulation 191 that is used with the inhalation device 100.
  • Tracer material formulation 191 is selected to substantially duplicate the aerosol properties of a drag to be administered to the patient.
  • Container 195 encloses a drag formulation 196 to be administered to the patient, this drag formulation has properties when aerosolized that are substantially duplicated by tracer material formulation 191.
  • the patient interface 120 may be any device that allows effective testing and treatment of the patient.
  • One embodiment of the patient interface uses Y-connector 121 that connects the patient to the inhalation device 100.
  • Inlet leg 122 of Y-connector 121 is connected to connection line 1 11 that provides a flow of aerosol and gas or air.
  • Outlet leg 123 of Y connector is connected to connection line 141.
  • a mouthpiece 125 is connected to Y- connector 121 at common arm 124. Nose clip 121 is typically used to prevent nasal inhalation or exhalation.
  • the term mouthpiece includes all means (e.g.
  • An inhalation filter 161 is typically located at the mouthpiece 125 or at common leg 124. Inhalation filter 161 intercepts and captures substantially all of a tracer material, drag or other aerosolized material that is drawn into contact with the filter 161 as the patient inhales during the first filter test phase of the method.
  • Bypass filter 163 captures substantially all of the aerosolized material flowing from connection line 111 that bypasses filter 161 and enters leg 123 of the Y-connector as the flow of gases flows toward and into connector 141.
  • the patient interface is constructed so that the device 100 is sealed and usable with the filters 161, 163 present or removed.
  • filter 161 When filter 161 is used it is placed so that all air inspired from device 100 by the patient is filtered and is of a type wherein substantially all aerosol particles are removed so that the patient is not exposed to the aerosolized tracer materials.
  • n some em o men s s con emp a e a e yp ca n a a on ev ce a is used to administer the drag is not actually the same device used in the tests but is substantially similar to that used in the tests.
  • a substantially similar device may be used for example when the tracer material 191 is radioactive.
  • a substantially similar device is considered to be one that acts substantially the same way as the original tested device. Acting substantially the same way includes for example generating an aerosol having substantially the same particle size distribution and properties that provides substantially the same deposition and distribution characteristics in the patient, generating substantially the same amount of aerosol in given time period, and so on.
  • An example of a substantially similar device would be a device from the same manufacturer of the same model type or design.
  • the substantially similar inhalation device has properties that provide patient drug deposition amounts or distributions that are within 20% of the amounts and distributions of materials in the tested device, more preferably within 10% of the tested device and most preferably within 5% of the tested device (e.g. the generation of aerosol such as the pulse volume in the Battelle inhalation device should be narrowly controlled to assure the substantially the same deposition amounts during the drag dosing phase as during the testing phase).
  • the generation of aerosol such as the pulse volume in the Battelle inhalation device should be narrowly controlled to assure the substantially the same deposition amounts during the drag dosing phase as during the testing phase.
  • a presently preferred device with which to practice the invention is the Battelle inhalation device.
  • This device provides the necessary elements for successful patient testing and administration of drag.
  • Two of the key elements for the successful delivery of drags via inhalation are the generation of aerosols having appropriate properties for delivery to the target in the patient and the ability to deliver an accurate dose in a reproducible fashion.
  • Particle size and flow rate are major parameters that determine the site of deposition within the respiratory tract which may range from maximal deposition in the oropharynx, trachea or main bronchi to deposition deep in t e ungs.
  • the Battelle inhalation device is typically for mouth only respiration although the device can be used for nasal inhalation when treatment of the nasal passages is required.
  • the control unit controls the gas supply pulse to the nebulizer for a predetermined time interval.
  • the atomized drug accumulates in a plenum 109 and is inhaled naturally by a patient through a dosing breath.
  • the patient breathes fresh air during the normal preparatory breaths of the cycle although various medicines may be incorporated in the air to assist the patient in controlling his/her breathing, reduce coughing, dilate the bronchi and so on.
  • the Battelle inhalation device preferably uses a Pari LC Plus nebulizer
  • pressurized air from the air supply.
  • the aerosolized drag decelerates and accumulates inside the plenum 109 until it is pulled into the patient's lung naturally upon a dosing breath..
  • inspiration the patient is typically reminded by the operator or the inhalation device to perform a breath hold which will increase drug deposition.
  • the patient's expired air then passes through a Pall HME 15/22 exhaust filter before being released from the inhalation device.
  • Pulmonary administration by inhalation may be accomplished by means of producing liquid or powdered aerosols, for example, by the devices disclosed herein or by using any of various devices known in the art.
  • Various delivery devices are commercially available and all or portions thereof can be employed, e.g. Ultravent nebulizer (Mallinckrodt, Inc, St. Louis, MO); Acorn II nebulizer (Marquest Medical Products, Englewood, CO); Ventolin metered dose inhalers (Glaxo Inc., Research Triangle Park, North Carolina); Spinhaler powder inhaler (Fisons Corp., Bedford, MA) or Turbohaler (Astra).
  • Ultravent nebulizer Maligninckrodt, Inc, St. Louis, MO
  • Acorn II nebulizer Marquest Medical Products, Englewood, CO
  • Ventolin metered dose inhalers Gaxo Inc., Research Triangle Park, North Carolina
  • Spinhaler powder inhaler Fesons Corp., Bedford, MA
  • Turbohaler Astra
  • Such devices typically
  • Nebulizer devices such as those in Greenspan et al US patents 5,511,726 and 5, 115,971 are useful in the invention. These devices use electrohydrodynamic forces o pro uce a ine y v e aeroso av ng un orm y s ze rop e s y e ec ca atomization. While the Greenspan devices use piezoelectric materials to generate electrical power any power source is acceptable to produce the electrohydrodynamic forces for nebulization. Elecrohydrodynamic devices such as those disclosed in the following patents or patent applications are useful in the invention: see for example US 4,358,059;
  • Formulations for the tracer materials and drags used herein are selected so that the tracer material substantially duplicates the aerosol properties of the drag with which it is used. This duplication or mimicking of properties important in the deposition of drag in the pulmonary system allows the use of a tracer material for deposition tests without the presence of the drag. Because the patient is not exposed to the drug in the test phase risk of injury to the patient is reduced.
  • a tracer material formulation that has been found useful for tests in the delivery of doxorubicin is a 20/80 (v/v) ethanol/water mixture of Tc-99m DTPA.
  • This formulation produces an aerosol whose aerosol properties (e.g. particle size) and pulmonary deposition properties substantially mimic or duplicate those of a 20/80 ethanol /water (V/V) doxorubicin formulation.
  • a Tc-99m DTPA filter test and the optional scintigraphy test practiced according to the method of the invention can serve as a means of predicting total body deposition or pulmonary doxorubicin deposition and distribution and be used to determine dosing parameters (e.g.
  • doxorubicin in the total body, pulmonary system, bronchi or lung.
  • the ratio of ethanol to water in the above formulation may be varied to the extent that it does not substantially alter the pulmonary deposition properties of the aerosol containing the tracer material or drug.
  • Formulations having substantially the same aerosol properties and deposition properties for a particular tracer material and a particular drag can readily be ascertained by those skilled in the art once knowing the teachings of the present invention. Included in these formulations are tracers based on radioactive materials such as Tc-99m, dense materials, colored materials, fluorescent materials and the like.
  • antineoplastic drags include taxanes such as paclitaxel and docetaxel; vinca alkaloids such as vincristine, vinorelbine, vindesine, and vinblastine; anthracyclines such as daunorubicin, methoxymorpholino doxorubicin, epirabicin, cyanomorpholinyl doxorubicin, and idarabicin; carboplatin and cisplatin.
  • Additional drugs included in the formulations of the present invention are antineoplastic agents not mentioned above but included in the groups represented by alkylating agents, DNA crosslinking agents, antimetabolites, topoisomerase inhibitors; and tubulin inhibitors.
  • aerosols containing liposomes and other particles that enclose drugs, or that have drags attached to their surface, and are useful in the treatment of disease.
  • physiologically inert gases may be used as an aerosolizing agent for the formulations.
  • Other components such as physiologically acceptable surfactants (e.g. glycerides and particularly lung surfactants), excipients (e.g. lactose), carriers, preservative agents, and diluents may also be included in the formulations.
  • physiologically acceptable surfactants e.g. glycerides and particularly lung surfactants
  • excipients e.g. lactose
  • carriers e.g. lactose
  • preservative agents e.g. diluents
  • diluents include chemoprotectants that may be added to the formulations and used to protect the pulmonary system from the toxic effects of the drags.
  • a typical example of a useful pulmonary protectant is dexrazoxane.
  • the solution or suspension of the Tc-99m DTPA and/or drag may be any pharmaceutically acceptable vehicle such as water, ethanol, PEG or combinations thereof so long as the herein-required properties for the aerosol are obtained.
  • the solution or suspension may also contain other surfactants such as lecithin or other phospholipids, to facilitate the deposition of the DTPA under conditions where large amounts of mucus may be present.
  • Materials specifically added to alter aerosol properties to obtain the required aerosol properties may also be present. The important factor to keep in mind in making the various formulations is that the tracer material, and its carrier and any associated materials carried therewith, must have the substantially the same deposition characteristics as the drug that will later be administered to the patient. Aerosol or Part c e Size
  • the aerosol particle size used in the method will be determined by the deposition site selected for treatment. Smaller particles are needed for treatment in the deep lung while larger particles are need for treatment of the proximal respiratory tract such as the bronchi. Typically particle sizes between 0J and 10.0 micrometers are useful in the present invention. For deposition within the central and peripheral compartments of the lung the particles should typically have a particle size of from about 1.0-5.0 ⁇ m with a GSD less than about 2.0. As is known in the art, particle sizes are selected depending on the site of desired deposition of the drug particles within the respiratory tract.
  • the initial dose of inhaled drag for human patients be about 1/20 to 1/2 of the maximum tolerated dose from a dog toxicity study in which the drug is administered to the dog by inhalation.
  • a more preferred initial dose for some drags is 1/10 to 1/3 the maximum tolerated dose for the dog.
  • the maximum tolerated dose in the dog is defined as the lowest dose of drug that produces mild to moderate microscopic pulmonary toxicity but no change in respiratory rate.
  • this inhaled dose in the dog is either the lung or total body deposited dose based upon a Tc-99m deposition test.
  • the Tc-99m is typically incorporated in the drag solution as a tracer.
  • the drag is administered to the dog via an inhalation device that does not have to be the same but may be the same or substantially the same as that used to treat the patient.
  • the initial human patient doses can be escalated as needed during treatment up to dose limiting toxicities in the patient by methods known to practitioners in the art.
  • the ultimate dose in human patients is typically 1/10 to twice that of the maximum tolerated dose in the dog as defined above.
  • the recommended initial starting dose for humans is about 0J3 mg/m 2 (based on body surface area) to about 0.4 mg/m 2 or about 1/10 the low dose (1.3 mg/m 2 single dose) to 1/3 the maximum tolerated dose from a dog toxicity study in which aerosolized doxorubicin was administered via an endotracheal tube.
  • the maximum tolerated dose in the dog was administered three mes a wee y n erva s an pro uce m o mo era e m croscop c pu monary toxicity but no change in respiratory rate as seen in dogs given higher doses.
  • 0J3 - 0.4 mg/m 2 body surface area
  • this dose can be escalated using predefined dose escalation criteria.
  • doxorubicin inhalation should be administered in a manner matched to the patient and particular neoplasm being treated.
  • Additional guidelines for dosages include those disclosed in copending US application for "Formulation and Method for Treating Neoplasms by Inhalation” filed concurrently herewith having attorney docket number 22000(1)971 ICIP, Michael E. Placke et al, and the same assignee as the present application, the contents of which are incorporated by reference as if fully rewritten herein.
  • the application particularly provides teaching of doses for the safe and efficacious inhalation of doxorubicin, paclitaxel, vincristine, vinorelbine, cisplatin, etoposide, 9-aminocamptothecin, and carboplatin. A portion of the guidelines included therein are repeated below:
  • the safe and effective range of doses of the inhalant antineoplastic drags in humans and animals are shown in Table 2 below. Larger animal dosages can be calculated by using multiples of the small animal based dose based on the known relationship of body weight to kg/m 2 of body surface area. The exact doses will vary depending upon such factors as the type and ' location of the tumor, the age and size of the patient, the physical condition of the patient and concomitant therapies that the patient may require. The dosages shown are for doses for one course of therapy. A course of therapy may be given, monthly, weekly, biweekly, triweekly or daily depending on the drug, patient, type of disease, stage of the disease and so on.
  • a course of therapy may include one dose to an extended dosage period lasting many months.
  • a course of therapy may include a minimum dose listed above or may include levels of drag that add up to the amount specified.
  • the drug is typically administered in small amounts over several breaths. Where the drug is administered over 20 breaths in a one day session the patient would receive 0.02 mg/m at each breath. However, the daily course of therapy would be considered to be 0.4 mg/m 2 . If the patient receives this one-day dose once a week for a six-week period the course of therapy is considered to be 6 x the daily dose or 2.4 mg/m 2 .
  • the doses may be given in single or divided amounts on a daily, multiple days, weekly, bi-weekly or monthly and may be repeated as needed to achieve the desired effects on the particular lung or respiratory tract tumor being treated or prevented.
  • the drugs are typically administered in cycles , that is the patient is treated for one or more periods after which there is a rest period of days or weeks. The treatment is then repeated.
  • the inhaled drugs may be given alone or in conjunction with drags administered by other routes such as IV, oral, intrapleural, or intratumoral for treating or preventing tumors outside of the respiratory tract.
  • ar ers use u or t e rags s e ere n are t ose at prov e ease o delivery to the patient by inhalation and are nontoxic in the concentrations administered.
  • Water, PEG, alcohol, propylene glycol, glycerol, and mixtures thereof are typical carriers presently preferred in the invention.
  • Drug concentration in the carrier may range from zero to saturation depending on the test or treatment involved, preferably 0.001 mg/mL to saturation.
  • the patient is trained in the type of breathing and the number of breaths required for the effective treatment of the patients disease state. For example, if deep lung deposition is desired the patient is trained to take deep dosing breaths and to retain them for a set period of time. This series is continued for the number of dosing breaths the patient requires. For deposition in the proximal airways shallower dosing breaths are practiced along with optional breath holding for the required number of breaths.
  • the patient performs the training sessions in conjunction with the inhalation device so that the patient is familiar and comfortable with its use. Patient breathing training in conjunction with the inhalation device and the method of administration of the present invention will result in more efficacious treatment.
  • a first embodiment contemplates performing a two step testing procedure for a patient that is determined to have a substantially normal pulmonary system followed by administering a drag based on the test.
  • a second embodiment contemplates performing a three step testing procedure on a patient that is determined to have a substantially impaired pulmonary .
  • a substantially normal or repeat patient would be treated with the two step testing procedure and a substantially impaired or high risk patient would be treated with the three step testing procedure.
  • the two step filter testing procedure contemplates developing dosing information for the individual patient using the following steps.
  • the first step includes a set of filters (inhalation filter 161 and blow-by filter 163) and is called the first filter test.
  • the second step (the second filter test) dispenses with at least the inhalation filter and applies a tracer material directly to the pulmonary system of a patient.
  • Both the first filter test and the second filter test develop data that is used in determining dosing information for treatment of the patient with the inhalation device 100.
  • the patient is instructed to breathe through the mouthpiece for a set number and type of breaths.
  • the breaths contemplated include a set of preparatory breaths numbering from zero to 20 during which no aerosolized tracer material is released by the inhalation device and a dosing breath for which a controlled dose of tracer material is released.
  • the patient then repeats the breathing procedure a predetermined number of times, typically zero to twenty times, more preferably one to ten times.
  • Most preferred is the actual breathing procedure used in the examples herein, two preparatory breaths followed by a dosing breath, with the breathing procedure repeated a total of five times.
  • a typical breathing sequence that is expected to provide good results for the filter test uses at least one to six preparatory breaths followed by a dosing breath and a breath hold period for each dosing breath. This sequence is repeated from one to six times.
  • a breath hold period may be useful during the first filter test to provide similar conditions as in the second filter test.
  • a breath hold period will aid in patient training and compliance during the second filter test.
  • the breath hold period will follow the dosing breath and will be from zero seconds (corresponding to no breath hold) up to 30 seconds. It is important to note that the breath hold period in the second filter test.
  • the preparatory breaths are typically normal breathing breaths; but, may be any found useful for providing good patient compliance and proper dosing during the following dosing breath.
  • the dosing breaths and the following breath-holding period are typically those found to provide proper pulmonary deposition and pulmonary distribution.
  • previous studies such as Bates, DV et al; Deposition and Retention Models for Internal Dosimetry of the Human Respiratory Tract; Health Physics; Pergamon Press; Vol. 12; 1966; pp. 173-207; Brain, JD et al; Deposition of Aerosol in the Respiratory Tract; Am Rev Resp Dis; 1979; Vol. 120; pp.
  • a tracer material is released as an aerosol and administered to the patient.
  • inhalation filter 161 no tracer material actually reaches the patient but is filtered out and captured on inhalation filter 161.
  • blow-by tracer materials are captured on blow-by filter 163.
  • the inhalation filter 161 and blow-by filter 163 are removed and tested for the amount of tracer material present.
  • Tracer material testing is a well-known technique and known techniques such as the use of well counters for radioactive materials; detectors for fluorescent materials, color detectors for color, or absorption; and the like are contemplated for the test herein. Specifically preferred is Tc-99m.
  • the amount of tracer material present on the inhalation filter 161 represents the amount of tracer material that would have been inhaled but for the presence of the inhalation filter 161.
  • a second test termed the second filter test
  • the foregoing procedure is essentially repeated except that inhalation filter 161 is removed and exhaust filter 140 or an optional replacement blow-by filter 164 (that replaces blow-by filter 163 that was removed for analysis in the first filter test) is used to measure blow-by and exhaled tracer material.
  • the replacement blow-by filter 164 may be dispensed with if an exhaust filter 140 is used and analyzed, however, a replacement blow-by filter 164 is preferred in order to obtain similar operating conditions.
  • the patient breathes through the mouthpiece as before but for a new set of predetermined number of breaths.
  • the breathing pattern includes a set of preparatory breaths (typically numbering the same as in the first filter test and of the same type) during which no aerosolized tracer material is released by the inhalation device.
  • a dosing breath is taken for which a controlled dose of tracer material is released and inhaled followed by a breath hold period.
  • the breath hold period may be any period from zero seconds (corresponding to no breath hold) up to 30 seconds.
  • the breath hold period selected is that which will provide proper deposition of aerosol at the desired site in the pulmonary system.
  • the patient repeats the preparatory breaths, dosing breath, and breath hold breathing procedure a predetermined number of times, typically five to fifty times, preferably 15 to 40 times and most preferably 20 to 30 times.
  • the actual number actually used in the examples herein and presently most preferred are two preparatory breaths followed by a dosing breath and five second breath holding period, with the sequence repeated twenty-four times.
  • the number of breaths in the first and second filter test should be at least that number that will give good distribution of aerosol without significant variation due to breathing variations in the patient. While a large number of breaths reduces variability, this must be balanced with patient abilities, comfort and compliance.
  • a second tracer material is administered to the patient, except this time since filter 161 has been removed and the patient inhales the tracer material.
  • This second tracer material may be the same or different from the first tracer material.
  • an optional new by-pass , filter is now used to measure the amount of blow-by material and the amount of exhaled material from the patient. This breathing sequence and filter collection and measurement allows for correction of the inhaled dose determined in the first filter test to compensate for the amount of material that is inhaled and then exhaled by the patient but never deposited in the patient. The amount of tracer material actually deposited in the patient and its relative ratio to the total amount aerosolized by the inhalation device is then determined.
  • the results of the first and second filter tests are then used to calculate the number of dosing breaths needed, and optionally the corrections to the inhalation procedure or to the inhalation device, in order to deliver the predetermined dose to the patient in the subsequent administration step.
  • Corrections to the device typically include resetting the aerosol generation time, the delay time between activation of the nebulizer and aerosolization, pressure used to drive the nebulizer, amount of drug placed in the device, adjustment of the device to obtain a different particle size, and so on.
  • Adjustments in the breathing procedure typically include using a different types of dosing breath, adjusting the breath hold period, using a different type of preparatory breath, changing the number of each type of breath and so on.
  • the patient breathes from the inhalation device used for the tests, or a substantially similar device, for the calculated number of dosage breaths.
  • the number of preparatory breaths between each dosing breath step is typically the same for both filter tests.
  • the concentration of doxorubicin in the formulation should be reduced. This will have the effect of increasing the number of breaths required to obtain the predetermined dose and reduce the variability due to having one or more breaths in the sequence in which greater or lesser amounts of drag are inhaled compared to the other breaths.
  • a major advantage of the method of the invention is that the drag with which the patient is to be treated is not used during the first and second filter tests. This reduces risk to the patient. Thus the drag is not present in the patient's system during administration of tracer material, which if radioactive may result in unintended . , that the three step testing procedure is not used, when only the hereto described two step filter testing method is used without the deposition distribution information, tracer materials having less risk to the patient than radioactive tracers, such as colored or fluorescent markers can be used to determine the number of breaths for proper dosing.
  • the initial filter tests and pulmonary distribution test may be performed using radioactive tracer material with scintigraphy while subsequent tests for the same patient use the filter technique and non- radioactive tracer materials that rely on fluorescence, density, absorption or colored tracer materials.
  • non-radioactive tracers allows the patient to be tested on the day of treatment immediately before administration of the drag and provides for reducing patient variability from day to day as is further discussed below.
  • a further consideration for using a non-radioactive tracer on the day of treatment with a drag is that some drugs such as some antineoplastic drugs react differently in the body in the presence of radioactive materials.
  • a washout period of several days to allow radioactive material to clear the body before treatment with the drag. Waiting for the drag washout period to end introduces variability since typically several days elapse between test and administration of the drag.
  • this method of treatment is contemplated in another embodiment of the invention.
  • a third step provides for taking a scintigraphic image of the patient immediately after the second step. This third step provides information as to the distribution of the aerosolized tracer material in the patient.
  • a radiographic image of the patient is made using common imaging techniques.
  • regions of interest are defined in the image.
  • the region of interest may be the , , , both lungs.
  • the counts in the lungs are determined using imaging techniques. Next the counts in the kidneys, bladder, and those generally attributable to Tc-99m that has left the lungs are determined and these counts are added to the lung counts. Counts in the mouth, stomach and other areas are not counted toward the lung counts. Since the amount of tracer material that has been aerosolized, lost in the system and captured in the bypass filters 163, 164 and or exhaust filter 140 can be determined, the amount and percentage of tracer material in the lung can be calculated. Decay of radioactive tracer material is corrected by tracking time during the test procedure.
  • the amount of drug to be aerosolized is determined from the information obtained in either the two-step test or the three-step test. From the information obtained in either the two-step test or the three-step test one can determine the amount of drug to be aerosolized, inhalation device settings needed to obtain the required amount of aerosolized drug to be administered to the patient and the required number of dosing breaths needed to administer the predetermined dose of drag to the patient.
  • the drug is administered to the patient for the determined number of dosing breaths with the same inhalation device or a substantially similar inhalation device.
  • Additional embodiments of the invention include alternate methods of administering the proper dose that is generated and administered to the patient.
  • data generated in the filter tests and in the scintigraphy deposition tests have been used to determine the number of dosing breaths needed to administer the predetermined dose to the patient either as a total body dose or as a pulmonary system or lung dose. While this is the presently preferred method when using the Battelle inhalation device for determining how to properly dose the patient and is believed to provide the most accurate drug dose, alternate methods using time, generated aerosol determinations, and volume or weight changes of supply reservoirs are also contemplated as included within the scope of the invention. These alternate methods may find greater utility when using other inhalation devices. For example, when electrohydrodynamic devices are used to generate the aerosol, volume may be a preferred dosing parameter to provide proper drug dosage.
  • one additional embodiment for determining the proper dose includes a method of testing and administration utilizing a time period during which the patient inhales aerosol from the inhalation device. This embodiment is achieved by utilizing a time period to administer the tracer material during the first and second filter tests data to actually administer the drug to the patient. The time periods used in the first and second filter tests would typically be different, with the first filter test time typically shorter than the second filter test time.
  • Another embodiment for determining the proper dose to be administered to a patient includes a method of testing and administration utilizing the volume of drug that is aerosolized or delivered by the inhalation device.
  • This embodiment is achieved by tracking the amount of tracer material generated as an aerosol or the amount of tracer material that is consumed (reduction in weight or volume) in the nebulizer reservoir during the first and second filter tests. Subsequently, the amount of drag that needs to be generated as an aerosol, or the amount of drag that is to be consumed in the nebulizer reservoir is determined. The determination may be based in whole or in part on the filter test data to actually administer the drag to the patient. The amount of aerosol generated or the reduction in volume or weight of the reservoir material would typically be different. During the first filter test, the amount of aerosol generated or the weight or volume reduction in the reservoir would typically be less than during the second filter test.
  • a third major embodiment contemplates the classification of patients into two categories and their subsequent treatment. First a determination is made whether the pulmonary function of the patient is substantially normal or substantially impaired; then a determination is made of whether the patient is in a low risk or high risk category for treatment by inhalation with the drug selected for treatment; when the pulmonary function of the patient is determined to be substantially normal and the patient is determined to be in a low risk category for treatment by inhalation with the drug then the patient follows the method using the two step test and administration of drug; when the pulmonary function of the patient is substantially impaired or the patient is in the high risk category for administration of the drag then the patient follows the method using the three step test and administration of the drag.
  • a subject was tested in a facility, which has equipment, and personnel required to detect gamma radiation by various means.
  • a gamma camera was used to image a radiation source directly to determine the unobstructed (non-attenuated) radiation from the source.
  • a second image was obtained from the posterior side of the subject's chest with the radiation source positioned against the front of the subject's chest. This procedure was repeated with the camera anterior to the chest and the radiation source behind the subject's chest.
  • the difference in the radiation detected by the gamma camera without the subject positioned between the radiation source and the camera and the amount of radiation detected when the subject's chest is placed between radiation source and the camera represents the amount of radiation attenuated by the subject's chest. This difference is converted to percentage radioactivity lost when divided by the amount of radiation detected directly (without the subject present) and is referred to as the attenuation factor.
  • the gamma camera used above to determine the attenuation factor was used to determine the amount of Tc-99m (for example, counts per minute or cpm) in the lungs and upper body of the patient.
  • the previously determined attenuation factor was used to correct the Tc-99m cpm for the attenuation losses.
  • the amount of Tc-99m deposited in the different regions of the respiratory tract was then expressed as a percentage of the amount of Tc-99m aerosolized.
  • the method of this example gave widely varying results that were not easily reproducible even with the same patient. This was due to errors during the correction for attenuation losses.
  • the method of the invention using two filter tests eliminates the need to determine the attenuation factor in the aforementioned Example 1 and provides . according to a predetermined dose.
  • the filter tests used alone allow accurate control of total body dose and a reliable dose that is delivered to the pulmonary system as is further explained below.
  • the inhalation device 100 is fitted with an inhalation filter 161 which is capable of removing the Tc-99m that would be inhaled by a patient as well as a blow -by filter 163 to collect Tc-99m which is exhaled.
  • Inhalation filter 161 used to determine the amount of Tc-99m that would be inhaled is placed just before the mouth.
  • the patient is then instructed to inhale the Tc-99m as in Example 1 for a short period of time, (e.g. 0.5 to 2.0 minutes) using a dosing breath pattern of two preparatory breaths followed by a dosing breath and optional breath hold.
  • the preparatory breath and dosing breath sequence is repeated five times.
  • the number of dosing breaths during which Tc-99m aerosol was available is recorded.
  • Filters 161, 163 are then removed from the device and are placed in a well or gamma counters to determine the amount of radioactivity present.
  • the patient is instructed to resume the Tc-99m inhalation for a predetermined number of preparatory and dosing breaths (in this case two preparatory breaths for each dosing breath with and optional breath hold and a total of twenty- four dosing breaths, without the inhalation filter 161 in place, for a brief period of time, usually about five minutes.
  • An additional filter 164 can be used to replace filter 163 and can be used to measure blow-by and exhaled aerosol during the second filter test.
  • blow-by aerosol and exhaled aerosol can be determined using only the exhalation filter 140 in the second filter test .
  • Filter 164 or exhaust filter 140 are measured for radioactivity as well as that for the tubing and the amount remaining in the nebulizer. From this information one can determine the relative amount of aerosol that the patient inhaled compared to the amount actually nebulized. This factor can then be used to determine the required amount of drag that must be nebulized in order to properly dose the patient with a predetermined amount of the drug. If the patient is considered to have substantially normal pulmonary system function so that deposition will follow a pattern determined in previous studies of the deposition patterns of typical patients or of a previous study of this particular patient, then the test stops here. The drag is then administered in accordance to the number of dosing breaths determined from the information developed.
  • This example illustrates the use of the invention to provide accurate predetermined drug dosages to selected parts of the pulmonary system, in this case the lungs. If the patient is determined to have substantial pulmonary system impairment or is determined to not be eligible for the administration of drag according to the method of Example 2 alone, then the patient is quickly placed before a gamma camera. Scintigraphic images of the torso to determine the whole body count and chest and upper abdomen are developed and are used to determine the percentage of Tc-99m present in the lung, kidneys and urinary bladder. The Tc-99m in the kidneys and bladder are added to that in the lung since it is known that inhaled Tc-99m DTPA is excreted via the kidneys. Tc-99m that is swallowed is not absorbed but excreted in the feces and is therefore not counted toward the lung counts.
  • Amount ofTc-99m deposited in lung (69.7% x 5,487) 3,824 cpm/dosing breath
  • Example 3 A method according to Example 3 wherein the information on the distribution of the Tc-99m in the respiratory tract is used to select a particular particle size distribution such that the anticancer drag will be deposited at the tumor site. For example, for those cancers which may be more prevalent in the proximal airways, a larger particle size is preferred.
  • a larger particle size is preferred.
  • An aerosol of the anticancer drag would be prepared with the same particle size and would be delivered to the target site in the amount calculated per Example 3.
  • This example illustrates a clinical study using the Battelle inhalation device.
  • the study included both healthy volunteers and patients with mild to moderately severe respiratory impairment.
  • the objectives were to evaluate the performance of the inhalation device, the tolerability of the ethanol vehicle and to characterize deposition and distribution of the vehicle with Tc-99m DTPA by means of a filter test and scintigraphy. It was shown that the particle size generated by the Battelle - similar to that of doxorubicin in the same vehicle.
  • a Tc-99m DTPA filter test and the optional scintigraphy test according to the method of the invention can serve as a means of predicting inhalational doxorubicin deposition and distribution and be used to calculate the dosing parameters (e.g. number of dosing breaths a patient will need to take) in order to achieve the deposition of a specific quantity of doxorubicin in the total body, pulmonary system, or lung.
  • dosing parameters e.g. number of dosing breaths a patient will need to take
  • the Battelle inhalation device was programmed for automatic filling of the plenum every third breath.
  • some subjects especially patients with impaired respiratory function, were not able to maintain the rhythmic breathing pattern required by the automatic mode operation of the device. Therefore, the option of utilizing a manual operation mode was introduced.
  • an operator such as a respiratory therapist operates the aerosol generator, resulting in filling of the plenum when the subject is ready to take a dosing breath.
  • the breathing pattern is typically the same for automatic or manual mode, however, the manual mode provides more flexibility and allows the respiratory therapist to time the filling of the plenum for when the subject is ready to take a dosing breath. With adequate coaching, this manual mode appears to be more appropriate for both the therapist and subjects.
  • the tests in this example were designed to evaluate the reproducibility of pulmonary deposition of Tc-99m DTPA (10 milli curies in 2 ml 20% ethanol/80% water V/V vehicle) administered by inhalation with the Battelle inhalation device on two occasions at least 7 but no more than 30 days apart to the same person.
  • the differences between this example and Example 6 were that the manual mode was used for operating the delivery device throughout the tests and that patients used a mouthpiece with a mouthseal and noseclip, without a face mask. In Example 6, the patients had noted moderate discomfort with the use of the mask.
  • the patients followed a set breathing pattern of two normal preparatory breaths followed by a dosing breath and a breath hold - an approximately five second breath hold for each of the twenty- four dosing breaths (approximately 5-7 minutes). Images were obtained immediately after each inhalation . , test was performed to determine the fraction of inhaled dose deposited in the body.
  • Table 3 displays the total body and pulmonary deposition data for the two inhalation phases for the nine patients who completed both phases.
  • the mean total body deposition (expressed as percent nebulized retained in the body) was 32.44% and 32.78% for inhalation phases 1 and 2 , respectively.
  • the absolute mean difference between the two phases was 3.81 . . . . pulmonary deposition (expressed as percent of nebulized retained in the lungs) was 21.10% and 21.46%, for inhalation phases 1 and 2, respectively.
  • the absolute mean difference was 3J9 percentage points (range 0.75% to 5.85%) with a standard deviation of 2.01.
  • the results show an entirely different story.
  • the first three columns in Table 3 list the results for different subjects tested on two different days with the two step filter tests, and shows the percentage of nebulized aerosol that is retained in the body of the subject.
  • the second three columns list results for the same subjects tested on two different days with the two step filter test plus the scinti graphic distribution test that shows the percent of nebulized aerosol that was retained in the lungs.
  • the data for subject Table 3 show that although the retained body aerosol was fairly constant day to day for some subjects (e.g. such as 001, 002, 003) other subjects such as 004 and 008 had large differences.
  • patient 004 would have received about a 30% higher body dose on one day as compared to the next as determined by the filter test and about 25% more in the lung as determined by the filter and scintigraphic tests.
  • Patient 008 would have received about a 35% higher body dose and about a 27% higher lung dose one day compared to the next.
  • nebulizer output in mL for each dosing breath taken by the subject.
  • the data was generated using a different nebulizer on each test day for each subject. Thus no subject was ever treated twice with the same nebulizer.
  • the highest nebulizer output was found with patient 001 on day 1 while the lowest nebulizer output was found with subject 006 on day 1. This represents a low to high percentage output difference of about 37 %.
  • the present invention can correct for the differences between patients and for the same patient on different days or in different parts of a patient's treatment particularly when the patient is tested and treated according to the precepts of the present invention.
  • the present invention is especially efficacious when testing and treatment are closely spaced in time as within a few days or most preferably on the same day.
  • the present invention can eliminate the differences in inhalation devices by testing the patient with the device immediately prior to treatment with a drag by using a non-radioactive easily tolerated tracer in the filter tests.
  • the first three digits in the subject designation represents the patient number (e.g. 001), the digit after the period represents the test day (1 st or 2 nd ), (e.g. 001 J designates data for patient 1 taken on the first test day; 001.2 designates data for patient 1 taken on the second test day.
  • the dosing parameters for administering the predetermined dose of drag to the patient will be determined based on the filter tests (as total body dose) or the Tc-99m deposition pattern test by scintigraphy (as pulmonary deposited dose) and in the main embodiment will be expressed as the number of dosing breaths that the patient will have to inhale. The calculations are described in detail below.
  • the patient should be comfortably seated and fitted with a suitable mouthpiece.
  • a nose clip is preferably used to prevent breathing through the nose.
  • Appropriate site personnel, usually a respiratory therapist, will undertake patient coaching and operation of the inhalation device. Once the patient is ready to begin, there will be a brief training session until the patient is familiar with the required breathing pattern.
  • the patient will be instructed to breathe normally for several preparatory breaths (preferably two) followed by instructions to take the proper dosing breath (e.g. "breathe deeply and hold for so many seconds" if deep lung deposition is desired) during which the patient is to take the proper dosing breath and breath hold.
  • the instruction would be to take a deep breath to full lung capacity with a breath hold of preferably 1 to 30 seconds and most preferably about 1 to 10 seconds. After the patient is comfortable with this breathing pattern the filter tests and the tracer material inhalation will begin followed by the pulmonary deposition tests it desired.
  • the Battelle inhalation device will be readied and 10 millicuries of Tc-99m DTPA will be added to 2ml of the vehicle in a syringe and injected into the inhalation device.
  • the Tc-99m filter test is designed to determine the fraction of the inhaled aerosol that is deposited in the patient and to quantify the "blow-by" aerosol which is not available to the patient for inspiration. It consists of two filter tests. 1) Filter test -For the first filter test, two filters, an inhalation filter (immediately in front of the mouthpiece) and a "blow-by" filter will be inserted into the inhalation device (see Figures 1 and 2 for details). The patient will be instructed to breathe normally for two breaths followed by a "breathe deeply and hold for a count of five" . , towards the end of the second normal inspiration, the therapist will activate the solenoid by pressing and releasing the pendent switch.
  • the filter test continues with the breathing pattern of two normal preparatory breaths followed by a dosing breath for a total of five dosing breaths.
  • the number of dosing breaths taken (corresponding to the number of plenum fills) will be shown on the display panel of the Battelle inhalation device.
  • the Battelle inhalation device At the end of the first filter test, the Battelle inhalation device will be turned off and the mouthpiece and nose clip temporarily removed.
  • the patient will be refitted with the mouthpiece 125 and noseclip 121.
  • the breathing pattern will continue with two normal preparatory breaths followed by a dosing breath and five-second breath hold with the therapist activating the inhalation device as described above.
  • the duration of the second filter test is typically twenty- four dosing breaths (approximately 5-7 minutes). It is expected that this will result in the deposition of approximately 2mCi Tc-99m DTPA in the lungs.
  • the Battelle inhalation device 100 Upon completion of the 24 dosing breaths, the Battelle inhalation device 100 will be turned off and the mouthpiece 125 and nose clip 121 will be removed.
  • a gamma well counter (dose calibrator) is typically used to assay small items (inhalation and blow-by filters) and a gamma camera is typically used for the larger items (gas lines, exhaust filter, etc.), however the gamma camera can be used for all items if desired.
  • the calculations are based upon data from a two part Tc-99m tracer material filter test for the total body dose and upon data from the optional three part test for the pulmonary dose. Subject #403 completed the tests as outlined herein. The first filter test had two , sequence was repeated five times. During the second filter test two preparatory breaths were taken for each dosing breath with a 5 second breath hold, this procedure however, was repeated only for a total of 16 dosing breaths rather than the desired 24. The calculations below take this into account in determining dosing parameters for the total body dose and the pulmonary dose.
  • Approximately 0.5 mCi Tc-99m is introduced into a 250 mL saline bag that only has approximately 50 mL of saline. This saline bag is measured for radioactivity in a dose calibrator as well as using the gamma camera. The ratio of radioactivity determined by the gamma camera to that obtained by the dose calibrator is used to correct all dose calibrator counts to gamma camera radioactivity.
  • Inhalation filter (MF) the amount of tracer material, Tc-99m, on the inhalation filter represents the amount of material that would be inhaled with the required number of dosing breaths, in this case, five dosing breaths.
  • Blow-by filter (BF) - the amount of tracer material, Tc-99m, on the blow-by filter represents the amount of material that was aerosolized, but by-passed the mouthpiece and was not available to the subject for inhalation during the required number of dosing breaths.
  • Exhaust (Ex) the amount of tracer material, Tc-99m, on the exhaust filter and in the exhaust tubing represents the total amount of exhaled tracer material and the amount of blow-by tracer material. - , drag, that is deposited (retained) in the body.
  • Amt. nebulized (cpm) Pre-Syringe cts (cpm) - Post-syringe cts (cpm) - amt remaining in nebulizer (cpm)
  • This number is the total deposited dose.
  • STEP 2 Express radioactivity in cpm.
  • Tc-99m in the saline bag is used to convert radioactivity measured in the dose calibrator to cpm obtained by gamma camera imaging.
  • the pre-syringe corrected time (8.8914 mCi) is converted to cpm as follows:
  • Decayed saline bag cpm
  • mCi Decayed saline bag dose calibration
  • STEP 3 Determine amount inhaled.
  • STEP 5 Determine Total Number of Dosing Breaths.
  • the total number of dosing breaths is the sum of the number of dosing breaths during the filter test and the number of dosing breaths during the second filter test. In the above example, the total number of dosing breaths is equal to 21 (5 + 16).
  • STEP 6 Determine amount exhaled.
  • STEP 7 Determine the amount nebulized.
  • Amt nebulized (cpm/DB) pre-syringe cts (cpm) - post-syringe cts (cpm) - amt remaining in nebulizer (cpm)
  • STEP 8 Determine amount nebulized per dosing breath.
  • STEP 9 Determine amount deposited (retained) in the body.
  • the deposition efficiency from step 10 can then be used to determine various dosing parameters for administering the antineoplastic drug on a total body basis.
  • the dose deposited in the pulmonary system or a region of interest within the pulmonary system can be determined. For example the counts in the pulmonary system, bladder, and kidneys can be added since it is know that Tc-99m exits the lung as is explained in one of the examples. The ratio of the pulmonary dose to the total body dose then gives the percent deposited dose for the pulmonary system. A similar calculation can be done for a region of interest within the pulmonary system.
  • Table 7 illustrates the radioactive counts per minute (cpm) for various regions of the body and the clock times associated with the measurements. Table 7
  • STEP 11 Determine total counts for the body.
  • STEP 12 Determine total lung.
  • STEP 13 Determine amount in lung. Amount in lung (cpm/DB) Total Lung Counts x Amount Deposited in Body in cpm/DB
  • the fraction deposited in the lung can be used to determine the proper dosing parameters on a region of interest. In this case the lungs.
  • Example 3 shows how the deposition fraction or efficiency is used to calculate a dosing parameter, in that case the number of dosing breaths required to administer a predetermined dose to a patient.
  • Example 8 This example illustrates an actual treatment of a patient using the procedures described herein and particularly the detailed description of Example 8.
  • the patient's body surface area was determined using the nomograms for calculating adult body surface area published in ASFS Drag Information 96, Gerald K McEvoy, Ed., American Society of Health-System Pharmacists, page 2780.
  • the patient weighed about 64 kg and had a height of 160 cm. Thus the calculated body surface area used was about 1.7 m 2 .
  • the baseline pre-syringe counts per minute of injected test material were 1,352,918 cpm.
  • the number of deep breaths during the filter test was five (5) for which the plenum was filled five (5) times with fresh nebulized material.
  • the counts on the mouth filter that would correspond to the inhaled portion were 26,494 cpm or 5,299 cpm per deep breath.
  • the counts for the blow-by filter test were 24,364 cpm or 4,873 cpm per deep breath.
  • the plenum was filled 24 times with fresh nebulized material during the test.
  • the counts on the exhaust were 130,438 cpm or 5,435 cpm .
  • u - five (5) and the number of deep breaths for the exhaust was 24 for a total of 29 deep breaths for the entire deposition test.
  • the amount remaining in the nebulizer was
  • Table 8 illustrates the counts per minute (cpm) for various parts of the body during the scintigraphic test. The measurements are correlated to clock times for correction of decay as needed. The amounts in the kidneys in this case were negligible, however, in other embodiments particularly with other tracer materials these measurements may be important. The amounts of tracer material entering the blood stream from ingested tracer material in the stomach were previously found not to contribute to amounts in the kidneys and bladder. Table 8
  • kidneys and bladder are from inhaled portions.
  • the patient was given the Tc 99m deposition test as described earlier with the results shown in Table 8.
  • the nebulizer was filled with 2 mL of a 20% ethanol in water solution containing 10 mC Tc 99m DTPA.
  • the patient then inhaled five (5) deep breaths with the mouth filter and blow-by filter in place.
  • a gamma camera was then used to image the patient's lungs to verify that no Tc 99m had been inhaled. The latter measurement served as the background level.
  • the mouth filter and blow-by filter were then removed for determination of radioactivity deposited on the filters and the patient was then instructed to take 24 additional deep breaths without the filter in place.
  • the patient was then placed under a gamma camera for scintigraphic analysis and subsequent quantification of the distribution of the Tc 99m-DTPA in the lung and other organs.
  • the exhaust filter and associated conduits were evaluated for deposition.
  • the radioactivity data (cpm) was collected and the number of deep breaths of doxorubicin aerosol required were calculated from the radiation counts in the filters and from the organs as noted above .
  • a desired deposited dose of doxorubicin of 0.4 mg/m with a body surface area of 1.7 m .
  • With a total body deposition efficiency of . . . formulation had a concentration of 4 mg/mL. Since each pulse delivered 0.092 mg, the number of required deep breaths was determined to be sixteen (16) (see calculation below:
  • the patient came in for treatment once every three weeks for a total of three doxorubicin treatments by inhalation.
  • the daily course of treatment of 0.4 mg/m 2 gave an overall dose of 1.2 mg/m " for the total course of treatment.
  • the lung tumors did not grow during this time and the patient exhibited no ill effects.
  • the doses were well tolerated and the procedure was successful in avoiding toxicity and providing a controlled dose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une méthode visant à traiter un patient malade par inhalation d'un médicament généralement toxique ou présentant un faible index thérapeutique, consistant: (a) à effectuer un premier test filtrant sur le patient à l'aide d'un marqueur et d'un dispositif d'inhalation, au cours duquel le patient n'est pas exposé au marqueur, afin d'obtenir un premier ensemble de données, (b) à effectuer un second test filtrant sur le patient à l'aide d'un marqueur et d'un dispositif d'inhalation, au cours duquel le patient inhale le marqueur, afin d'obtenir un deuxième ensemble de données, (c) à effectuer éventuellement un test de dépôt sur le patient afin d'obtenir un troisième ensemble de données, (d) à déterminer à partir du premier et du deuxième ensemble de données et, éventuellement, du troisième ensemble de données, les paramètres de dosage nécessaires pour administrer par inhalation une dose prédéterminée de médicament au patient, et (e) à administrer le médicament au patient à l'aide du dispositif d'inhalation selon les paramètres de dosage déterminés, ces paramètres de dosage déterminant la quantité de médicament que le patient inhalera et retiendra sur une base corporelle totale ou dans son système pulmonaire.
PCT/US2000/005559 1999-03-05 2000-03-03 Methode visant a administrer un medicament par inhalation de maniere sure et efficace WO2000051491A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33936/00A AU3393600A (en) 1999-03-05 2000-03-03 Method for safely and effectively administering a drug by inhalation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26374899A 1999-03-05 1999-03-05
US09/263,748 1999-03-05

Publications (1)

Publication Number Publication Date
WO2000051491A1 true WO2000051491A1 (fr) 2000-09-08

Family

ID=23003077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005559 WO2000051491A1 (fr) 1999-03-05 2000-03-03 Methode visant a administrer un medicament par inhalation de maniere sure et efficace

Country Status (2)

Country Link
AU (1) AU3393600A (fr)
WO (1) WO2000051491A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066103A2 (fr) * 2000-03-03 2001-09-13 Battelle Memorial Institute Formulation et methode de traitement des neoplasmes par inhalation
WO2009002267A1 (fr) * 2007-06-28 2008-12-31 Dustgun Technologies Ab Système d'exposition
US8955512B2 (en) 2001-06-05 2015-02-17 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US10363384B2 (en) 2011-03-16 2019-07-30 Koninklijke Philips N.V. System and method of remotely monitoring and/or managing the treatment of a plurality of subjects with aerosolized medicament
US11642473B2 (en) 2007-03-09 2023-05-09 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
CN116159231A (zh) * 2023-04-24 2023-05-26 乐恩(北京)医药技术有限公司 一种下呼吸道喷雾控制处理系统及方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2346730A1 (de) * 1973-09-17 1975-04-17 Heyer Gmbh Carl Geraet zur herstellung eines programmierten therapeutischen aerosolregimes
US4703753A (en) * 1982-04-30 1987-11-03 Cadema Medical Products, Inc. Radioactive aerosol inhalation apparatus
US4741331A (en) * 1987-02-02 1988-05-03 Atomic Products Corporation Disposable radioactive aerosol inhalation apparatus
EP0302834A2 (fr) * 1987-08-07 1989-02-08 SORIN BIOMEDICA S.p.A. Procédé de préparation d'aérosols destinés aux examens scintigraphiques de la ventilation du poumon et dispositif approprié
US5829436A (en) * 1996-02-05 1998-11-03 Aradigm Corporation Ventilation imaging using a fine particle aerosol generator
WO1999044664A2 (fr) * 1998-03-05 1999-09-10 Battelle Memorial Institute Systeme et methode de dosage pulmonaire

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2346730A1 (de) * 1973-09-17 1975-04-17 Heyer Gmbh Carl Geraet zur herstellung eines programmierten therapeutischen aerosolregimes
US4703753A (en) * 1982-04-30 1987-11-03 Cadema Medical Products, Inc. Radioactive aerosol inhalation apparatus
US4741331A (en) * 1987-02-02 1988-05-03 Atomic Products Corporation Disposable radioactive aerosol inhalation apparatus
EP0302834A2 (fr) * 1987-08-07 1989-02-08 SORIN BIOMEDICA S.p.A. Procédé de préparation d'aérosols destinés aux examens scintigraphiques de la ventilation du poumon et dispositif approprié
US5829436A (en) * 1996-02-05 1998-11-03 Aradigm Corporation Ventilation imaging using a fine particle aerosol generator
WO1999044664A2 (fr) * 1998-03-05 1999-09-10 Battelle Memorial Institute Systeme et methode de dosage pulmonaire

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066103A3 (fr) * 2000-03-03 2002-03-21 Battelle Memorial Institute Formulation et methode de traitement des neoplasmes par inhalation
WO2001066103A2 (fr) * 2000-03-03 2001-09-13 Battelle Memorial Institute Formulation et methode de traitement des neoplasmes par inhalation
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US10350157B2 (en) 2001-05-24 2019-07-16 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US9440034B2 (en) 2001-05-24 2016-09-13 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US8955512B2 (en) 2001-06-05 2015-02-17 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US9308208B2 (en) 2001-06-05 2016-04-12 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US9439907B2 (en) 2001-06-05 2016-09-13 Alexza Pharmaceutical, Inc. Method of forming an aerosol for inhalation delivery
US9687487B2 (en) 2001-06-05 2017-06-27 Alexza Pharmaceuticals, Inc. Aerosol forming device for use in inhalation therapy
US11065400B2 (en) 2001-06-05 2021-07-20 Alexza Pharmaceuticals, Inc. Aerosol forming device for use in inhalation therapy
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9370629B2 (en) 2003-05-21 2016-06-21 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US11642473B2 (en) 2007-03-09 2023-05-09 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US8555873B2 (en) 2007-06-28 2013-10-15 Inhalation Sciences Sweden Ab Exposure system
WO2009002267A1 (fr) * 2007-06-28 2008-12-31 Dustgun Technologies Ab Système d'exposition
US10363384B2 (en) 2011-03-16 2019-07-30 Koninklijke Philips N.V. System and method of remotely monitoring and/or managing the treatment of a plurality of subjects with aerosolized medicament
CN116159231A (zh) * 2023-04-24 2023-05-26 乐恩(北京)医药技术有限公司 一种下呼吸道喷雾控制处理系统及方法

Also Published As

Publication number Publication date
AU3393600A (en) 2000-09-21

Similar Documents

Publication Publication Date Title
Newman et al. Pressurised aerosol deposition in the human lung with and without an" open" spacer device.
Hess et al. The effect of heliox on nebulizer function using a β-agonist bronchodilator
EP0940154B1 (fr) Dispositif pour administrer des aérosols de médicaments
US9180263B2 (en) Laboratory animal pulmonary dosing device
Newman et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand‐held multidose nebulizer
US4790305A (en) Medication delivery system
US8141551B2 (en) Mouthpiece and flow rate controller for intrapulmonary delivery devices
Borgström et al. Total and regional lung deposition of terbutaline sulphate inhaled via a pressurised MDI or via Turbuhaler®
Newman et al. Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern.
US20010035183A1 (en) Method for improving lung delivery of pharmaceutical aerosols
Smaldone Drug Delivery via Aerosol Systems: Concept of" Aerosol Inhaled"
JP2007533411A5 (fr)
JP2003522003A (ja) 薬剤投与装置
Newman et al. Efficient drug delivery to the lungs from a continuously operated open-vent nebulizer and low pressure compressor system
Pitcairn et al. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort
O'Callaghan et al. Evaluation of techniques for delivery of steroids to lungs of neonates using a rabbit model.
Votion et al. Aerosol deposition in equine lungs following ultrasonic nebulisation versus jet aerosol delivery system
Epstein et al. A comparison of three means of pressurized aerosol inhaler use
Newman et al. Comparison of beclomethasone dipropionate delivery by Easyhaler® dry powder inhaler and pMDI plus large volume spacer
WO2000051491A1 (fr) Methode visant a administrer un medicament par inhalation de maniere sure et efficace
Steed et al. Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from the prototype III hand-held multidose Respimat nebuliser
Dahlbäck et al. Controlled aerosol delivery during mechanical ventilation
Zainudin et al. Influence of breathing pattern on lung deposition and bronchodilator response to nebulised salbutamol in patients with stable asthma.
US20090285763A1 (en) Infant aerosol drug delivery systems and methods
Pitcairn et al. Lung deposition of salbutamol from the Leiras metered dose powder inhaler

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WPC Withdrawal of priority claims after completion of the technical preparations for international publication
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase